IVERIC bio (ISEE) Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last year. There are currently 10 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ISEE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ISEE, but not buy additional shares or sell existing shares.
View ISEE analyst ratings or view top-rated stocks.

10 brokers have issued 1-year target prices for IVERIC bio's stock. Their ISEE share price forecasts range from $19.00 to $35.00. On average, they predict the company's stock price to reach $25.75 in the next twelve months. This suggests that the stock has a possible downside of 35.5%.
View analysts price targets for ISEE or view top-rated stocks among Wall Street analysts.

IVERIC bio, Inc. (NASDAQ:ISEE) released its quarterly earnings data on Wednesday, March, 1st. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.10. During the same quarter in the previous year, the business posted ($0.29) EPS.

ETFs with the largest weight of IVERIC bio (NASDAQ:ISEE) stock in their portfolio include AltShares Merger Arbitrage ETF (ARB), AltShares Event-Driven ET (EVNT) and Vanguard Russell 2000 Growth ETF (VTWG).Vanguard Russell 2000 ETF (VTWO).

6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC).

IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."

IVERIC bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State Street Corp (3.40%), TCG Crossover Management LLC (1.78%), Nuveen Asset Management LLC (0.74%), Segantii Capital Management Ltd (0.64%), Picton Mahoney Asset Management (0.00%) and Marshall Wace LLP (0.44%). Insiders that own company stock include Anthony S Gibney, Calvin W Roberts, Christopher Paul Simms, David Francis Carroll, David R Guyer, Glenn Sblendorio, Keith Westby and Pravin Dugel.
View institutional ownership trends.

One share of ISEE stock can currently be purchased for approximately $39.95.

IVERIC bio (NASDAQ:ISEE) has a market capitalization of $5.50 billion. The company earns $-185,210,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

The company employs 163 workers across the globe.

IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The official website for the company is ivericbio.com. The company can be reached via phone at (609) 474-6755 or via email at kathy.galante@ivericbio.com.